Now Available: Meningococcal Vaccines Market Forecast and Growth 2016-2026

Meningococcal
Vaccines Market
Share, Global Trends,
Analysis, Research, Report,
Opportunities,
Segmentation and Forecast,
2016
Future Market Insights
www.futuremarketinsights.com
sales@futuremarketinsights.com
Future Market Insights (FMI) is a premier provider of syndicated research reports, custom research reports, and consulting
services. We deliver a complete packaged solution, which combines current market intelligence, statistical anecdotes,
technology inputs, valuable growth insights, aerial view of the competitive framework, and future market trends.
We provide research services at a global as well as regional level; key regions include GCC, ASEAN, and BRIC.
Our offerings cover a broad spectrum of industries including Chemicals, Materials, Energy, Technology, Healthcare, and
Retail.
We have a global presence with delivery centers across India specializing in providing global research reports and country
research reports. FMI is headquartered out of London, U.K., with a state-of-the-art delivery center located in Pune, India.
We combine our knowledge and learning from every corner of the world to distill it to one thing – the perfect solution for
our client.
Research Capabilities
Sector Coverage








Customized Research
Syndicated Research
Investment Research
Social Media Research
Automotive and Transportation
Electronics, Semiconductor, and ICT
Retail and Consumer Products
Industrial Automation and Equipment
Customized
Research
Subscription Information
Syndicated
Research
For detailed subscription information please contact
Investment
Research
T: +44 (0) 20 7692 8790 | D: +44 20 3287 4268
Social Media
Research
Hari. T (Sr. Manager - Global Business Development)
Email: hari.t@futuremarketinsights.com




Chemicals & Materials
Food and Beverages
Services and Utilities
Energy, Mining, Oil, and Gas
Report
Description
Report Description
Meningococcal disease is a potentially fatal illness caused due to bacterium known as
Neisseria meningitides. The bacteria is known to cause serious infection in the meninges,
which are thin layers of connective tissues surrounding the brain and spinal cord.
Common clinical symptoms of meningococcal disease are meningitis, bacteremia, and
pneumonia. Other less common indications include myocarditis, endocarditis or
pericarditis, arthritis, conjunctivitis, urethritis, pharyngitis, and cervicitis. Symptoms
associated with these disease include high fever, neck stiffness, confusion, nausea,
vomiting, lethargy, and petechial rashes.
Meningococcal vaccines are known to be found on the World Health Organization’s List of
Essential Medicines. The bacteria can be classified into over 10 serotypes based in their
immunologic reactivity. Currently, globally marketed meningococcal vaccines are of four
types - polysaccharide-based, bivalent (Serogroup A and C), trivalent (Serogroup A, C and
W-135), and tetravalent (Serogroup A, C, Y and W-135). There is currently only one
vaccine available for Serogroup B in the US, while it account for over one-third of the
disease cases in the country. The nature and components of the vaccines are purified,
heat-stable, lyophilized capsular polysaccharides derived from the meningococci of the
respective serogroups.
Request free sample Report: http://www.futuremarketinsights.com/reports/sample/repgb-1252
Report
Description
Report Description
Disease epidemiology of the meningococcal disease has undergone a radical change over
the last century. Case-fatality ratios have witnessed a decline of from a high of 70% in the
first part of the twentieth century to less than 15% after 2000. Of late the disease caused
by Serogroup Y has increased from prevalence rate of 2% to over 35% between 1990 and
2005. The disease is contractible in nature primarily through antimicrobial
chemoprophylaxis. There are currently three meningococcal vaccines available in the US
to prevent this life-threatening disease. However, these vaccines frequently feature
under the list of critical drugs in shortage.
Meningococcal Vaccines Market: Drivers and Restraints
The primary driver of meningococcal vaccines are introduction of advanced serotype B
vaccines from large global drugmakers such as Novartis and Pfizer. The expansion of
routine immunization programs across all parts of the world is much needed for the
commercial success of these vaccines. Increase in funding from the government of
compulsory immunizations at birth will also reduce out-of-pocket expenses of patients
and increase affordable access to meningitis vaccines. Further, higher annual
meningococcal disease incidence among infants and healthy young adults also is likely to
encourage use of the vaccine.
Request for TOC: http://www.futuremarketinsights.com/toc/rep-gb-1252
Report
Description
Report Description
The prime barriers of the market include price wars for the vaccines from comparable
drugmakers that may wipe out a greater customer base and reduce overall customer
coverage. The other barrier includes increasing financial austerity in the European
nations, which is expected to hamper the R&D base for the vaccines. Further, serotype
mismatch and less than optimum coverage across countries is likely to negatively affect
the demand for the vaccines. A delay in assessing the disease epidemiology over regular
intervals due to cost issues may negatively impact the market for meningococcal vaccines
over the long-term in the developing nations.
Meningococcal Vaccines Market: Segmentation
Global Compression Therapy Devices is further segmented into these following types:
By Product Type
• Monovalent
• Bivalent
• Trivalent
• Tetravalent or Quadrivalent
By formulation
• Polysaccharide-based
Report
Description
Report Description
• Conjugate-based
• Combination-based
By indication
• Pneumonia
• Meningitis
• Bacteremia
• Others (arthritis, conjunctivitis, Urethritis)
Browse full report: http://www.futuremarketinsights.com/reports/meningococcalvaccines-market
Meningococcal Vaccines Market: Overview
With the advancement of research and development, increase in awareness of disease
incidence and increasing government support in routine immunizations the
meningococcal vaccines Market is gaining traction as a treatment of choice among
patients. This market is expected to grow at a healthy CAGR in the forecast period (20152025).
Report
Description
Report Description
Rising prophylactic vaccination among infants, who tend to cover the largest endemic
population are expected to drive the market in the forecast period.
Meningococcal Vaccines Market: Region-wise Outlook
Depending on geographic regions, global compression therapy market is segmented into
seven key regions: North America, South America, Eastern Europe, Western Europe, Asia
Pacific, Japan, and Middle East & Africa.
In terms of geography, North America dominates the Meningococcal Vaccines Market
market, followed by Europe. Growing aging population and increasing prevalence of
diabetes are also supporting the growth of compression therapy market in this regions.
India, China, and Japan are expected to be the fastest-growing markets for compression
therapy in Asia.
Meningococcal Vaccines Market: Key Players
Some of the key players in compression therapy market are GlaxoSmithKline PLC, JNInternational Medical Corporation, Novartis International AG, Sanofi SA, Pfizer, Inc. and
Baxter International, Inc
Thank You!
To know more about us, please visit our website:
www.futuremarketinsights.com
For sales queries or new topics email us on:
sales@futuremarketinsights.com
For other queries contact: Mr. Sudip Saha
Future Market Insights: 616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States
T: +1-347-918-3531 | D: +1-845-579-5705